Jan 12,2020

Cecelia Health Continues Rapid Growth & Expansion Into Telemedicine

Cecelia Health, a leading technology-enabled chronic disease management company based in New York City, has continually innovated for over a decade to transform lives and health outcomes for patients and drive ROI for health plans, pharma and medical device companies and self-insured employers.

PRODUCT

#telehealth

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 15,2020

Tandem Diabetes Care Announces Commercial Launch of the t:slim X2 Insulin Pump with Control-IQ Technology in the United States

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its commercial launch of the t:slim X2™ insulin pump with Control-IQ™ technology, an advanced hybrid-closed loop feature designed to help increase time in range (70-180 mg/dL)1

PRODUCT

#insulin pump

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 19,2020

Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

DexCom, Inc. and Insulet Corporation, have announced a global commercialization agreement to combine current and future Dexcom continuous glucose monitoring systems (CGM) with Insulet’s trusted tubeless insulin delivery Pod into the Omnipod Horizon™ System for automated insulin delivery, currently in pivotal trial.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Feb 20,2020

Diabeloop launched a large clinical study to support its iController’s FDA clearance

Diabeloop is happy to announce, at the ATTD Conference (February 19th-22nd), that the CERITD sponsored DBLUS real-life clinical trial dedicated to FDA submission has begun. Patients are equipped with the Dana-i pump (SOOIL), the 3rd pump which is interoperable with the Diabeloop iController.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 24,2020

Advanced Hybrid Closed Loop System Early Feasibility Data on Patients Undergoing Unannounced Meal Challenges Shows Promising Results

Medtronic plc(opens new window) (NYSE:MDT), the global leader in medical technology, today announced a successful conclusion to the 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020), which took place in Madrid, Spain, from February 19 - 22, 2020.

CLINICAL STUDY

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Feb 25,2020

One Drop Increases Accuracy of AI-powered Hypoglycemia and Hyperglycemia Predictions and Introduces Alert Capability for People Using Continuous Glucose Monitors

The results of a recent study show that One Drop’s AI-powered glucose predictions are 91.9% accurate for hypoglycemia ("low") and 91.6% accurate for hyperglycemia ("high"), demonstrating greater accuracy than other notable providers.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 25,2020

Nemaura Medical Plans Head-to-Head Study with Major Glucose Monitoring System

Studies planned to compare sugarBEAT® and major continuous glucose monitor sensor, seeking to position sugarBEAT® as both a possible alternative and complementary device for people with diabetes

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 26,2020

Study Demonstrates Remote CGM Initiation Successful at Improving Diabetes Outcomes and Quality of Life

Cecelia Health worked with The Jaeb Center for Health Research (JCHR) with support from The Helmsley Charitable Trust on a study that demonstrated successful remote continuous glucose monitor (CGM) initiation and sustained CGM use to improve diabetes outcomes and quality of life for people living with diabetes.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 03,2020

Nemaura Medical Launches sugarBEAT® App on Play Store Ahead of its Planned Commercial Launch of BEAT®diabetes Subscription Service

sugarBEAT® App is now available on Play Store with iOS app planned to follow, ahead of the planned BEAT®diabetes subscription service launch.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 10,2020

Nemaura Medical enters into multiple verbal non-binding agreements for its sugarBEAT® platform

Nemaura Medical, Inc., a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor, together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching, announced it has entered in to multiple verbal non-binding agreements for sugarBEAT with the aim of securing regional and global partnerships.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM